Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...

The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – a fall of around 12% since the start of 2024 – and isn't yet completed. On the German ...

The initial results from the Bayer Carbon Program are in – and they’re significant. According to Nori, a carbon removal issuing program, registry and marketplace, over 125,000 regenerative tonnes from ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...